Bacteria: Gram-negative

Diarrheagenic Escherichia coli

Shiga toxin-producing E. coli (STEC) including O157; enteroaggregative (EAEC); enteroinvasive (EIEC); enteropathogenic (EPEC); enterotoxigenic (ETEC)

General medical information for education only, not medical advice. Treatment considerations summarize published guidance at drug-class level; therapy is chosen by the treating clinician using susceptibility results, local resistance patterns and current guidelines.

Overview

Pathotypes of E. coli that cause diarrhea through toxins or by attaching to or invading the intestinal lining. Spread through contaminated food and water and person to person.

Infections

STEC: bloody diarrhea and hemolytic uremic syndrome (HUS). EAEC: persistent diarrhea. EIEC: dysentery-like illness. EPEC: infant diarrhea. ETEC: watery traveler's diarrhea.

Signs and symptoms

Watery or bloody diarrhea, abdominal cramps, nausea; fever is often absent with STEC. Reduced urine output and pallor after STEC diarrhea suggest HUS.

Antibiotic and antimicrobial resistance

Resistance varies; susceptibility testing applies when treatment is considered.

Treatment considerations

Mainly fluids and supportive care. Antibiotics are generally avoided for STEC because they may increase the risk of HUS; selected cases of other pathotypes, such as severe traveler's diarrhea, may be treated.

Infection control and public health

STEC is a nationally notifiable condition. Contact precautions and hand hygiene in facilities.

Escherichia coli O157 cell with flagella, transmission electron micrograph
Escherichia coli O157 with flagella, transmission electron micrograph. Public domain. Image source
Gram-negative rods, schematic
Gram-negative rods. Schematic, not to scale; InnovexLab.

Sources

  1. CDC. E. coli infection.
  2. IDSA. Infectious Diarrhea guideline.

Sources accessed November 2026. Links open external sites that InnovexLab does not control.

Medical disclaimer

This page is general educational information summarized from published public-health and professional-society guidance. It is not medical advice, a diagnosis or a treatment recommendation, and reading it does not create a clinician–patient relationship with InnovexLab. Decisions about testing, diagnosis and treatment belong to the treating clinician, using the patient’s history and examination, laboratory and susceptibility results, local resistance patterns and current guidelines. Guidance changes over time; consult the original sources for the latest version. InnovexLab provides this information as is and does not warrant that it is complete or current.

Patients with questions about their health should contact their own healthcare provider. In an emergency, call 911.

Sources, image credits and editorial policy

Discuss a testing program with InnovexLab

Review the panel that fits your patients, its specimen requirements, and how results and billing work.